

Company name MediWound **Website** <https://www.mediwound.com/>

CEO name Ofer Gonen

- **Executive Summary / Investment Rational** - MediWound: A global leader in wound care with 20+ years of research, development, manufacturing, and commercialization of innovative treatments for severe burns and chronic ulcers. NexoBrid® provides effective, non-surgical enzymatic debridement for deep thermal burns, available in the USA, EU, and Japan. EscharEx® is in late-stage development for venous leg ulcers.
- **Core Technology** - Bromelain-Based Debridement: A proteolytic enzyme mixture enriched with Bromelain from pineapple stem. It selectively removes denatured collagen in burn eschar without harming healthy tissue. Its unique composition also degrades non-viable proteins (e.g., fibrin, elastin) in chronic wounds, aiding healing. Bromelain's anti-inflammatory properties further support the wound healing process.
- **Product Profile/Pipeline** - NexoBrid: Approved in 44 countries, available in the USA, EU, and Japan for adults and pediatric patients. Effectively removes burn eschar in 4 hours, optimizing surge capacity in burn mass casualty incidents by eliminating the need for surgical excision, operating rooms, and surgical staff. EscharEx: In Phase III for Venous Leg Ulcers. In late-stage development for Diabetic Foot Ulcers.
- **Business Strategy** - MediWound is committed to making NexoBrid® accessible to burn patients worldwide. With a presence in 40+ countries, we expand through strong partnerships (e.g., Vericel (US), Kaken (Japan)), combining our innovation with local expertise. Total addressable market (TAM) – 500M US\$. Our collaboration with Mölnlycke Health Care strengthens EscharEx' s development, driving long-term value and advancing global wound care standards. TAM – 2B US\$.
- **What's Next?** NexoBrid will be recognized in EU for BMCI, optimizing surge capacity and stockpiled across all EU countries, alongside BARDA in the US. It is set to become the standard of care for deep burn eschar removal. EscharEx aims to complete Phase III for VLU and initiate Phase II/III for DFU. MediWound continues to enhance collaborations with leading wound care companies.